Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...
Penn Medicine is one of the nation’s most prestigious health systems. But a Philadelphia jury says it failed a 45-year-old woman in the most devastating way possible, awarding her $35 million after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback